الإحصائيات الأساسية
| LEI | 549300QJFAI7L6YHKG83 |
| CIK | 1645469 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Monopar Therapeutics Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 29, 2025 |
Calculation of Filing Fee Tables S-3 Monopar Therapeutics Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Equity Common Stock, par value $0. |
|
| August 29, 2025 |
Table of Contents As filed with the Securities and Exchange Commission on August 29, 2025 Registration No. |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2025 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-3 |
|
| August 12, 2025 |
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments Exhibit 99.1 Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments Wilmette, IL, August 12, 2025 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced second quarter 2025 financial results and recent de |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissi |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934(Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| May 13, 2025 |
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments EXHIBIT 99.1 Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments Wilmette, IL, May 13, 2025 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced first quarter 2025 financial results and recent develop |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2025 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001- |
|
| May 13, 2025 |
Consulting Agreement of pRx Consulting (Patrice Rioux) - effective January 1, 2025 EXHIBIT 10.1 CONSULTING AGREEMENT This Consulting Agreement (herein referred to as “Agreement”) is made and entered into on December 27, 2024, effective as of January 1, 2025 (the “Effective Date”), by and between Monopar Therapeutics Inc. (herein referred to as “Monopar”), a Delaware corporation, located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091, and pRx Consulting, LLC (herein referred |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| May 7, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission F |
|
| May 7, 2025 |
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 Exhibit 99.1 Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 WILMETTE, Ill, May 7, 2025 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson diseas |
|
| April 30, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte |
|
| March 31, 2025 |
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments EXHIBIT 99.1 Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments WILMETTE, Ill., March 31, 2025 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced fourth quarter and full-year 2024 financial results and summarized recent deve |
|
| March 31, 2025 |
As filed with the Securities and Exchange Commission on March 31, 2025 As filed with the Securities and Exchange Commission on March 31, 2025 Registration No. |
|
| March 31, 2025 |
Consulting Agreement of pRx Consulting (Patrice Rioux) – effective January 1, 2024 Exhibit 10.7 CONSULTING AGREEMENT This Consulting Agreement (herein referred to as “Agreement”) is made and entered into on December 26, 2023, effective as of January 1, 2024 (the “Effective Date”), by and between Monopar Therapeutics Inc. (herein referred to as “Monopar”), a Delaware corporation, located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091, and pRx Consulting, LLC (herein referred |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2024 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 |
|
| March 31, 2025 |
Employment Agreement of Quan Vu – effective March 3, 2025 Exhibit 10.17 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of February 27, 2025, by and between Quan Vu (“Executive”) and Monopar Therapeutics Inc. (the “Company”). Whereas, the Company desires to employ Executive as its Chief Financial Officer effective as of March 3, 2025 (the “Effective Date”), and Executive desires to serve in such cap |
|
| March 31, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Monopar Therapeutics Inc. |
|
| March 31, 2025 |
Description of Registered Securities EXHIBIT 4.1 DESCRIPTION OF REGISTERED SECURITIES We have the authority to issue 40,000,000 shares of Common Stock, $0.001 par value. Common Stock Voting Rights The holders of shares of our common stock are entitled to one vote per share for the election of directors and on all other matters submitted to a vote of stockholders. Shares of our common stock do not have cumulative voting rights. The el |
|
| March 31, 2025 |
2016 Stock Incentive Plan, as amended Exhibit 10.18 MONOPAR THERAPEUTICS INC. 2016 STOCK INCENTIVE PLAN AS AMENDED (Share amounts have been adjusted to reflect a 1 for 5 reverse stock split that became effective on August 12, 2024) 1. Purpose of the Plan. The purpose of this Plan is to enhance shareholder value by linking the compensation of officers, directors, key employees and consultants of the Company to increases in the price of |
|
| March 31, 2025 |
Subsidiaries of Monopar Therapeutics Inc. as of December 31, 2024 EXHIBIT 21.1 Subsidiaries of Monopar Therapeutics Inc. as of December 31, 2024 Name Direct Parent Ownership Jurisdiction of Incorporation Monopar Therapeutics Australia Ltd Pty Monopar Therapeutics Inc. 100% Australia Monopar Therapeutics, SARL Monopar Therapeutics Inc. 100% France |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissio |
|
| March 31, 2025 |
Exhibit 19.1 1000 Skokie Blvd., Suite 350 Wilmette, IL 60091 Telephone: (847) 388-0349 Date: March 3, 2025 Dear Officer, Director or Employee: Enclosed is a memorandum from Monopar Therapeutics Inc.’s appointed Insider Trading Compliance Officer, a copy of the Company’s Confidential Insider Trading Policy, and, for officers and directors, a summary of the Ownership Reporting and Short-Swing Tradin |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commis |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commis |
|
| February 14, 2025 |
EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedu |
|
| February 12, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 JOINT FILER 2 p25-0182exhibit991.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the nec |
|
| January 27, 2025 |
882,761 Shares Common Stock Offered by the Selling Stockholder Filed pursuant to Rule 424(b)(3) Registration No. 333-284304 PROSPECTUS 882,761 Shares Common Stock Offered by the Selling Stockholder This prospectus relates to the resale from time to time of up to 882,761 shares of our common stock, par value $0.001 per share (the “Common Stock”), issuable upon the exercise of 882,761 outstanding pre-funded warrants to purchase shares of our Common Stock held b |
|
| January 23, 2025 |
Monopar Therapeutics Inc. 1000 Skokie Blvd., Suite 350 Wilmette, Illinois 60091 January 23, 2025 Monopar Therapeutics Inc. 1000 Skokie Blvd., Suite 350 Wilmette, Illinois 60091 January 23, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Monopar Therapeutics Inc. Registration Statement on Form S-3 File No. 333-284304 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ |
|
| January 15, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Monopar Therapeutics Inc. |
|
| January 15, 2025 |
As filed with the Securities and Exchange Commission on January 15, 2025 Table of Contents As filed with the Securities and Exchange Commission on January 15, 2025 Registration No. |
|
| December 23, 2024 |
798,655 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-268935 Prospectus Supplement (To prospectus dated January 4, 2023) 798,655 Shares of Common Stock We are offering 798,655 shares of our common stock, $0.001 par value per share (“Common Stock”), pursuant to this prospectus supplement and the accompanying prospectus. Certain investors have agreed to purchase pre-funded warrants |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commis |
|
| December 23, 2024 |
Form of Registration Rights Agreement by and among Monopar Therapeutics Inc. and the Purchaser Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is dated as of December 23, 2024, by and among Monopar Therapeutics Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Securities |
|
| December 23, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 20, 2024, by and among MONOPAR THERAPEUTICS INC., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and each Purchaser is |
|
| December 23, 2024 |
EXHIBIT 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN |
|
| December 23, 2024 |
Exhibit 1.1 MONOPAR THERAPEUTICS INC. (a Delaware corporation) 798,655 Shares of Common Stock UNDERWRITING AGREEMENT December 20, 2024 Piper Sandler & Co. as Representative of the several Underwriters c/o Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Monopar Therapeutics Inc., a Delaware corporation (the “Company”), confirms its agreem |
|
| December 18, 2024 |
705,015 Shares Common Stock Offered by the Selling Stockholder Filed pursuant to Rule 424(b)(3) Registration No. 333-283537 PROSPECTUS 705,015 Shares Common Stock Offered by the Selling Stockholder This prospectus relates to the resale from time to time of up to 705,015 shares of common stock, par value $0.001 per share (the “Common Stock”), of Monopar Therapeutics Inc. by the selling stockholder identified in this prospectus (the “Selling Stockholder”), incl |
|
| December 17, 2024 |
MNPR / Monopar Therapeutics Inc. / Tactic Pharma LLC - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1 )* MONOPAR THERAPEUTICS INC (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 61023L207 (CUSIP Number) Tactic Pharma LLC c/o 1000 Skokie Blvd, Ste 350, Wilmette, IL, 60091 (847) 388-0349 (Name, address and telephone number of person authoriz |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commiss |
|
| December 6, 2024 |
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu Exhibit 99.1 Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu WILMETTE, Ill., December 5, 2024 — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the first patient ever dosed with MNPR-101-Lu. This novel therapeutic radio |
|
| November 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Monopar Therapeutics Inc. |
|
| November 29, 2024 |
As filed with the Securities and Exchange Commission on November 29, 2024 Table of Contents As filed with the Securities and Exchange Commission on November 29, 2024 Registration No. |
|
| November 8, 2024 |
Exhibit 99.1 Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare Disease Two Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid Cancers Wilmette, IL, November 8, 2024 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Na |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2024 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commiss |
|
| October 31, 2024 |
MNPR / Monopar Therapeutics Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment SC 13G 1 tm2427181d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Monopar Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 61023L207 (CUSIP Number) October 24, 2024 (Date of Event Which Requires Filing of this Statement) Check |
|
| October 31, 2024 |
EX-99.1 2 tm2427181d1ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of October 31, 2024 is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission |
|
| October 30, 2024 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 28, 2024, between Monopar Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| October 30, 2024 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT October 28, 2024 Rodman & Renshaw LLC 600 Lexington Avenue, 32nd Floor New York, New York 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Monopar Therapeutics Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of up to 1,181,540 shares (the “Shares”) of the Company’s |
|
| October 30, 2024 |
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock Exhibit 99.1 Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) – Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of its best |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commiss |
|
| October 29, 2024 |
1,181,540 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-268935 Prospectus supplement (To prospectus dated January 4, 2023) 1,181,540 Shares of Common Stock We are offering 1,181,540 shares of our Common Stock, $0.001 par value per share, pursuant to this prospectus supplement and the accompanying prospectus. Our Common Stock is listed for trading on the Nasdaq Capital Market under |
|
| October 28, 2024 |
EXHIBIT A Agreement of Joint Filing The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock of Monopar Therapeutics Inc. |
|
| October 28, 2024 |
Subject to completion, dated October 28, 2024 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-268935 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and not soliciting an offer to buy these securi |
|
| October 28, 2024 |
MNPR / Monopar Therapeutics Inc. / ASTRAZENECA PLC - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Monopar Therapeutics Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 61023L207 (CUSIP Number) October 23, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| October 24, 2024 |
Common Stock Investment Agreement Exhibit 10.2 COMMON STOCK INVESTMENT AGREEMENT This Common Stock Investment Agreement (the “Agreement”), dated as of October 23, 2024, by and among Monopar Therapeutics Inc., a Delaware corporation (the “Company”), and Alexion Pharmaceuticals, Inc., a Delaware corporation (the “Licensor”). Capitalized terms used herein but not otherwise defined shall have the meanings given to them in the License |
|
| October 24, 2024 |
License Agreement between Alexion and Monopar Exhibit 10.1 CERTAIN INFORMATION INDICATED BY [***] IN THIS EXHIBIT HAS BEEN OMITTED AS NOT MATERIAL AND PRIVATE OR CONFIDENTIAL LICENSE AGREEMENT Between Alexion Pharmaceuticals, Inc. and Monopar Therapeutics Inc. Dated as of October 23, 2024 Table of Contents TABLE OF CONTENTS 1 Definitions 1 2 Grant of Rights; Exclusivity 10 3 Development 12 4 Regulatory Activities 13 5 Commercialization and Di |
|
| October 24, 2024 |
Exhibit 99.1 Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate WILMETTE, Ill., October 24, 2024 — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that it has entered into an agreement with Alexion, AstraZen |
|
| October 24, 2024 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value per share, of Monopar Therapeutics Inc. and further agree to the filing o |
|
| October 24, 2024 |
MNPR / Monopar Therapeutics Inc. / TANG CAPITAL MANAGEMENT LLC Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commiss |
|
| October 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commiss |
|
| October 22, 2024 |
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024 Exhibit 99.1 Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024 WILMETTE, Ill, October 22, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the clinical and preclinical development of its novel first-in-class lead radio |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commiss |
|
| October 15, 2024 |
Exhibit 99.1 Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers WILMETTE, Ill., October 15, 2024 — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the filing of a provisional patent covering new therapeutic radiopharmaceuticals bas |
|
| October 7, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissi |
|
| October 7, 2024 |
Exhibit 99.1 Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers WILMETTE, Ill., October 7, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that the Phase 1a clinical trial for its novel therapeutic radiopharmaceutical MNPR-101-L |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commi |
|
| September 12, 2024 |
Exhibit 99.1 Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr WILMETTE, Ill., September 12, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced positive early data from its ongoing open-label MNPR-101-Zr Phase 1 imaging and dos |
|
| August 27, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissi |
|
| August 27, 2024 |
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule Exhibit 99.1 Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule WILMETTE, Ill., August 27, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requir |
|
| August 21, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissi |
|
| August 21, 2024 |
Exhibit 99.1 Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers WILMETTE, Ill., August 21, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced it has received Human Research Ethics Committee (HREC) clearance in Austral |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissi |
|
| August 14, 2024 |
Exhibit 99.1 Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr WILMETTE, Ill., August 14, 2024 — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the successful dosing of the first patient in its open-label Phase 1 imaging and dosi |
|
| August 9, 2024 |
Exhibit 99.1 Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments Initiated and Enrolling Patients into MNPR-101-Zr First-in-Human Phase 1 Radiopharma Clinical Trial MNPR-101 radio-immuno-therapeutic (RIT) Clinical Trial on Track to Initiate in Q4 2024 Wilmette, IL, August 9, 2024 – Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinicals |
|
| August 9, 2024 |
Exhibit 99.3 CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MONOPAR THERAPEUTICS INC. Monopar Therapeutics Inc. (the “Corporation”), a corporation existing under and by virtue of General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: 1. The name of the Corporation is Monopar Therapeutics Inc. 2. The Corporation’s Cer |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissio |
|
| August 9, 2024 |
Monopar Therapeutics Announces 1-for-5 Reverse Stock Split Exhibit 99.2 Monopar Therapeutics Announces 1-for-5 Reverse Stock Split WILMETTE, Ill., August 9, 2024 — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Company ex |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2024 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-3 |
|
| August 9, 2024 |
Employment Agreement of Karthik Radhakrishnan - effective July 1, 2024 Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of May 23, 2024, by and between Karthik Radhakrishnan (“Executive”) and Monopar Therapeutics Inc. (the “Company”). Whereas, the Company desires to employ Executive as its Chief Financial Officer effective as of July 1, 2024 (the “Effective Date”), and Executive desires to serve in s |
|
| July 22, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934(Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted |
|
| July 11, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934(Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted |
|
| July 9, 2024 |
Exhibit 99.1 Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr WILMETTE, Ill., July 9, 2024 — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the enrollment of the first patient in its first-in-human Phase 1 dosimetry a |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| June 11, 2024 |
Monopar and NorthStar Amend & Extend Collaboration Exhibit 99.1 Monopar and NorthStar Amend & Extend Collaboration Highlights: ● Builds on Companies’ respective core strengths ● Aligns intellectual property rights ● Establishes a long-term supply agreement under which NorthStar provides actinium-225 for Monopar’s development and potential future commercial programs WILMETTE, IL and Beloit, WI, June 11, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNP |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| June 10, 2024 |
Exhibit 99.1 Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting WILMETTE, Ill, June 10, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the preclinical developme |
|
| June 10, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| May 24, 2024 |
Monopar Announces CFO Succession Exhibit 99.1 Monopar Announces CFO Succession WILMETTE, IL., May 24, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that after a career spanning more than 35 years, Monopar’s Chief Financial Officer, Kim R. Tsuchimoto, will be retiring. Ms. Tsuchimoto will be transitionin |
|
| May 9, 2024 |
Exhibit 99.1 Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline Initiated MNPR-101-Zr First-in-Human Phase 1 Radiopharma Clinical Trial MNPR-101-RIT Phase 1 Clinical Trial Targeted for Launch as Early as Q4 2024 or Q1 2025 Wilmette, IL, May 9, 2024 – Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical‐-stage r |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission F |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2024 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001- |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissio |
|
| April 16, 2024 |
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings Exhibit 99.1 Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings WILMETTE, Ill, April 16, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that it has filed a provisional patent application pertaining to the recent advancements and optimiz |
|
| April 10, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissio |
|
| April 10, 2024 |
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients Exhibit 99.1 Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients WILMETTE, Ill, April 10, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its Phase 1 dosimetry clinical trial for its novel radiopharmaceutical imaging agent MN |
|
| March 28, 2024 |
Exhibit 10.1 CONSULTING AGREEMENT This Consulting Agreement (herein referred to as “Agreement”) is made and entered into on December 13, 2022, effective as of January 1, 2023 (the “Effective Date”), by and between Monopar Therapeutics Inc. (herein referred to as “Monopar”), a Delaware corporation, located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091, and pRx Consulting, LLC (herein referred |
|
| March 28, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissio |
|
| March 28, 2024 |
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments EXHIBIT 99.1 Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments WILMETTE, Ill., March 28, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments. Recent D |
|
| March 28, 2024 |
Compensation Recoupment Policy Exhibit 97 Compensation Recovery Compensation Recoupment Policy (Required by Nasdaq Listing Rule 5608) Subject to the limited exceptions set forth herein, with respect to the compensation of executive officers and former executive officers subject to this policy as described under “Applicability” below, Monopar Therapeutics Inc. |
|
| March 28, 2024 |
Subsidiaries of Monopar Therapeutics Inc. as of December 31, 2023 EXHIBIT 21.1 Subsidiaries of Monopar Therapeutics Inc. as of December 31, 2023 Name Direct Parent Ownership Jurisdiction of Incorporation Monopar Therapeutics Australia Ltd Pty Monopar Therapeutics Inc. 100% Australia Monopar Therapeutics, SARL Monopar Therapeutics Inc. 100% France |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 |
|
| March 28, 2024 |
Description of Registered Securities EXHIBIT 4.1 DESCRIPTION OF REGISTERED SECURITIES We have the authority to issue 40,000,000 shares of Common Stock, $0.001 par value. Common Stock Voting Rights The holders of shares of our common stock are entitled to one vote per share for the election of directors and on all other matters submitted to a vote of stockholders. Shares of our common stock do not have cumulative voting rights. The el |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| March 5, 2024 |
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program Exhibit 99.1 Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program WILMETTE, Ill., March 5, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced positive preclinical imaging data of a therapeutic radioisotope bound to its proprietary |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commis |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commis |
|
| February 27, 2024 |
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial Exhibit 99.1 Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial WILMETTE, Ill., February 27, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that the internationally recognized radiopharmaceutical physician, Professor Rodney Hicks, will be the lead investigato |
|
| February 22, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commis |
|
| February 22, 2024 |
Exhibit 99.1 Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers WILMETTE, Ill., February 22, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced promising preclinical imaging and therapeutic efficacy data for its MNPR-101 |
|
| February 20, 2024 |
Exhibit 99.1 Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers WILMETTE, Ill., February 20, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced it has received Human Research Ethics Committee (HRE |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commis |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: |
|
| November 9, 2023 |
EXHIBIT 99.1 Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments MNPR-101 Radiopharma Program to Enter First-in-Human Studies Potentially As Early As December of This Year Camsirubicin Phase 1b Trial Efficacy and Safety Data Highlighted at the 2023 CTOS Annual Meeting Wilmette, IL, November 9, 2023 – Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commiss |
|
| November 1, 2023 |
Exhibit 99.1 Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting WILMETTE, Ill, November 1, 2023 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for c |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commiss |
|
| August 30, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2023 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissi |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissi |
|
| August 10, 2023 |
EXHIBIT 99.1 Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments Camsirubicin Phase 1b Trial Currently at 5th Dose-Level (650 mg/m2), Generating Encouraging Results MNPR-101 Radiopharma Program Advancing Toward First-in-Human Studies Wilmette, IL, August 10, 2023 – Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmace |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-3 |
|
| August 8, 2023 |
Monopar Provides Encouraging Camsirubicin Clinical Data Update Exhibit 99.1 Monopar Provides Encouraging Camsirubicin Clinical Data Update WILMETTE, IL, August 8, 2023 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today provided an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft t |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissio |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2023 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| July 11, 2023 |
Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore Exhibit 99.1 Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore WILMETTE, Ill, July 11, 2023 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today announced a collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the National U |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| June 2, 2023 |
MNPR / Monopar Therapeutics Inc / Klunzinger Jeffrey R. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Monopar Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 61023L108 (CUSIP Number) May 26, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| June 1, 2023 |
EXHIBIT 99.1 Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update Patient in 520 mg/m2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment 3 of 3 patients in the 520 mg/m2 cohort achieved stable disease WILMETTE, Ill, June 1, 2023 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focus |
|
| June 1, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| May 11, 2023 |
Consulting Agreement of pRx Consulting (Patrice Rioux) – effective January 1, 2023 EXHIBIT 10.1 CONSULTING AGREEMENT This Consulting Agreement (herein referred to as “Agreement”) is made and entered into on December 16, 2022, effective as of January 1, 2023 (the “Effective Date”), by and between Monopar Therapeutics Inc. (herein referred to as “Monopar”), a Delaware corporation, located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091, and pRx Consulting, LLC (herein referred |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THER |
|
| May 11, 2023 |
EXHIBIT 99.1 Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments Camsirubicin Phase 1b Dose-Escalation Trial Enrolling 5th Dose-Level Cohort (650 mg/m2) MNPR-101 RIT Shows Promising Imaging and Therapeutic Preclinical Study Results Wilmette, IL, May 11, 2023 – Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2022 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THERAPEUT |
|
| April 28, 2023 | ||
| March 27, 2023 |
EXHIBIT 99.1 Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis WILMETTE, Ill, March 27, 2023 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced completion of |
|
| March 27, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissio |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissio |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2022 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THERAPEUT |
|
| March 23, 2023 |
Subsidiaries of Monopar Therapeutics Inc. as of December 31, 2022 EXHIBIT 21.1 Subsidiaries of Monopar Therapeutics Inc. as of December 31, 2022 Name Direct Parent Ownership Jurisdiction of Incorporation Monopar Therapeutics Australia Ltd Pty Monopar Therapeutics Inc. 100% Australia Monopar Therapeutics, SARL Monopar Therapeutics Inc. 100% France |
|
| March 23, 2023 |
EXHIBIT 99.1 Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments Validive® Phase 2b/3 VOICE Trial Anticipates Go/No-Go Interim Readout by End of Next Week Camsirubicin Phase 1b Dose-Escalation Trial Now Enrolling 5th Dose-Level Cohort (650 mg/m2) Wilmette, IL, March 23, 2023 – Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a |
|
| March 23, 2023 |
Description of Registered Securities EXHIBIT 4.1 DESCRIPTION OF REGISTERED SECURITIES We have the authority to issue 40,000,000 shares of Common Stock, $0.001 par value. Common Stock Voting Rights The holders of shares of our common stock are entitled to one vote per share for the election of directors and on all other matters submitted to a vote of stockholders. Shares of our common stock do not have cumulative voting rights. The el |
|
| March 23, 2023 |
EXHIBIT 10.1 CONSULTING AGREEMENT This Consulting Agreement (herein referred to as “Agreement”) is made and entered into on December 13, 2021, effective as of January 1, 2022 (the “Effective Date”), by and between Monopar Therapeutics, Inc. (herein referred to as “Monopar”), a Delaware corporation, located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091, and pRx Consulting, LLC (herein referre |
|
| February 27, 2023 |
EXHIBIT 99.1 Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials WILMETTE, Ill. And BELOIT, Wis., February 27, 2023 – Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, Ill.) and NorthStar Medical Radioisotopes, LLC (Beloit, Wis.), today announced an expansion of their radiopharmaceutical collaboration along with a new radi |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commis |
|
| February 14, 2023 |
EXHIBIT 99.1 Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin WILMETTE, Ill., February 14, 2023 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commis |
|
| January 26, 2023 |
EXHIBIT 99.1 Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT WILMETTE, Ill, January 26, 2023 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced it is planning |
|
| January 26, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIESANDEXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) ofTheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): January 26, 2023 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission File |
|
| January 18, 2023 |
EX-99.1 2 mnprex991.htm PRESS RELEASE EXHIBIT 99.1 Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2 WILMETTE, Ill, January 18, 2023 - Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life |
|
| January 18, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIESANDEXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| January 4, 2023 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-268935 PROSPECTUS $6,505,642 Common Stock In accordance with the terms of the Capital on DemandTM Sales Agreement entered into with JonesTrading Institutional Services LLC (?JonesTrading? or the ?Agent?), dated April 20, 2022, which we refer to as the Sales Agreement, we may offer and sell under this prospectus (?ATM Prospectus?) shares of our |
|
| December 29, 2022 |
Monopar Therapeutics Inc. 1000 Skokie Blvd., Suite 350 Wilmette, Illinois 60091 December 29, 2022 Monopar Therapeutics Inc. 1000 Skokie Blvd., Suite 350 Wilmette, Illinois 60091 December 29, 2022 VIA EDGAR US Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Monopar Therapeutics Inc. Registration Statement on Form S-3 File No. 333-268935 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Monopar Th |
|
| December 21, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Monopar Therapeutics Inc. |
|
| December 21, 2022 |
As filed with the Securities and Exchange Commission on December 21, 2022 Registration No. |
|
| December 12, 2022 |
EXHIBIT 99.1 Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration WILMETTE, Ill, December 12, 2022 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today released promising data with MNPR-20 |
|
| December 12, 2022 |
UNITED STATES SECURITIESANDEXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) ofTheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December 12, 2022 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission File |
|
| November 16, 2022 |
Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial EXHIBIT 99.1 Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial WILMETTE, Ill, November 16, 2022 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today released encouraging data from its ongoing Phase 1b o |
|
| November 16, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIESANDEXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2022 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissio |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2022 ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIESANDEXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) ofTheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): November 10, 2022 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission File |
|
| November 10, 2022 |
EXHIBIT 99.1 Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments Validive? Phase 2b/3 Interim Analysis on Track for Q1 2023 Camsirubicin Clinical Data at CTOS 2022 Next Week MNPR-202 Preclinical Data at ASH 2022 in December Wilmette, IL, November 10, 2022 ? Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceu |
|
| October 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIESANDEXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2022 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| October 5, 2022 |
EXHIBIT 99.1 Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis Interim Analysis Planned for Q1 2023 WILMETTE, Ill, October 5, 2022 ? Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of |
|
| August 12, 2022 |
As filed with the Securities and Exchange Commission on August 12, 2022 As filed with the Securities and Exchange Commission on August 12, 2022 Registration No. |
|
| August 12, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables S-8 (Form Type) Monopar Therapeutics Inc. |
|
| August 11, 2022 |
EXHIBIT 99.1 Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments Validive? Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe and Enrolling Patients Toward Interim Analysis Anticipated in Q1 2023 Camsirubicin Phase 1b Dose-Escalation Trial Now Dosing 4th Level Wilmette, IL, August 11, 2022 ? Monopar Therapeutics Inc. (Monopar or the |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissi |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2022 ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THERA |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2022 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| May 12, 2022 |
EXHIBIT 99.1 Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments Validive? Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward Interim Camsirubicin Phase 1b Dose-Escalation Trial Clears 3rd Dose Level, Now Enrolling 4th Wilmette, IL, May 12, 2022 ? Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceuti |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2022 ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THER |
|
| May 12, 2022 |
EXHIBIT 3.1 AMENDED AND RESTATED BY-LAWS OF MONOPAR THERAPEUTICS INC. (the ?Corporation?) ARTICLE I OFFICES Section 1.01 Registered Office. The registered office of the Corporation within the State of Delaware shall be located at either (a) the principal place of business of the Corporation in the State of Delaware or (b) the office of the corporation or individual acting as the Corporation?s regi |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIESANDEXCHANGECOMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) ofTheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): May 12, 2022 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 20, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SecurityExchangeName UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 20, 2022 |
Capital on DemandTM Sales Agreement with JonesTrading Institutional Services, LLC EX-1.1 2 mnprex11.htm SALES AGREEMENT EXHIBIT 1.1 Monopar Therapeutics Inc. Common Stock ($0.001 par value per share) Capital on Demand™ Sales Agreement April 20, 2022 JonesTrading Institutional Services LLC 211 East 43rd Street, 15th Floor New York, NY 10017 Ladies and Gentlemen: Monopar Therapeutics Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Jone |
|
| April 20, 2022 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-235791 PROSPECTUS SUPPLEMENT (To Prospectus dated January 13, 2020) $4,870,000 Common Stock In accordance with the terms of the Capital on DemandTM Sales Agreement entered into with JonesTrading Institutional Services LLC (?JonesTrading? or the ?Agent?), dated April 20, 2022, which we refer to as the Sales Agreement, we may offer and sell under |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissio |
|
| March 24, 2022 |
Description of Registered Securities EXHIBIT 4.1 DESCRIPTION OF REGISTERED SECURITIES We have the authority to issue 40,000,000 shares of Common Stock, $0.001 par value. As of March 11, 2022, there were 12,604,514 shares of our common stock issued and outstanding. We have reserved 3,100,000 shares of our common stock for issuance under our 2016 Stock Incentive Plan, as subsequently amended (the ?Plan?), and as of March 11, 2022, we h |
|
| March 24, 2022 |
Consulting Agreement of pRx Consulting (Patrice Rioux) – effective January 1, 2021 EX-10.5 7 mnprex105.htm CONSULTING AGREEMENT EXHIBIT 10.5 CONSULTING AGREEMENT This Consulting Agreement (herein referred to as “Agreement”) is made and entered into on December 24, 2020, effective as of January 1, 2021 (the “Effective Date”), by and between Monopar Therapeutics, Inc. (herein referred to as “Monopar”), a Delaware corporation, located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 6 |
|
| March 24, 2022 |
Form of Incentive Stock Option Agreement EXHIBIT 10.2 MONOPAR THERAPEUTICS INC. 2016 Stock Incentive Plan INCENTIVE STOCK OPTION AGREEMENT THIS INCENTIVE STOCK OPTION AGREEMENT (this ?Agreement?) is made as of [[grantdate]] (the ?Grant Date?) between MONOPAR THERAPEUTICS INC. (the ?Company?) and [[firstname]] [[lastname]] (referred to herein as ?Participant?). Terms used in this Agreement with initial capital letters without definitions |
|
| March 24, 2022 |
Consulting Agreement of pRx Consulting (Patrice Rioux) – effective October 1, 2021 EXHIBIT 10.6 CONSULTING AGREEMENT This Consulting Agreement (herein referred to as ?Agreement?) is made and entered into on September 29, 2021, effective as of October 1, 2021 (the ?Effective Date?), by and between Monopar Therapeutics, Inc. (herein referred to as ?Monopar?), a Delaware corporation, located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091, and pRx Consulting, LLC (herein referr |
|
| March 24, 2022 |
Amendment No 1 to Consulting Agreement of pRx Consulting (Patrice Rioux) – effective October 1, 2021 EXHIBIT 10.7 AMENDMENT NO. 1 TO CONSULTING AGREEMENT This Amendment No. 1 to Consulting Agreement (herein referred to as ?Amendment 1?) is made and entered into on November 17, 2021, by and between Monopar Therapeutics, Inc. (herein referred to as ?Monopar?), a Delaware corporation, located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091, and pRx Consulting, LLC (herein referred to as pRx), a |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2021 ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THERAPEUT |
|
| March 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissio |
|
| March 24, 2022 |
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments Validive? Phase 2b/3 VOICE Trial Continues Adding Sites in the U. |
|
| March 24, 2022 |
Subsidiaries of Monopar Therapeutics Inc. as of December 31, 2021 EXHIBIT 21.1 Subsidiaries of Monopar Therapeutics Inc. as of December 31, 2021 Name Direct Parent Ownership Jurisdiction of Incorporation Monopar Therapeutics Australia Ltd Pty Monopar Therapeutics Inc. 100% Australia Monopar Therapeutics, SARL Monopar Therapeutics Inc. 100% France |
|
| March 24, 2022 |
Form of Non-qualified Stock Option Agreement EXHIBIT 10.3 MONOPAR THERAPEUTICS INC. 2016 Stock Incentive Plan NONQUALIFIED STOCK OPTION AGREEMENT THIS NONQUALIFIED STOCK OPTION AGREEMENT (this ?Agreement?) is made as of [[grantdate]] (the ?Grant Date?) between MONOPAR THERAPEUTICS INC. (the ?Company?) and [[firstname]] [[lastname]] (referred to herein as ?Participant?). Terms used in this Agreement with initial capital letters without defini |
|
| March 24, 2022 |
Consulting Agreement of Christopher M. Starr – effective January 1, 2022 EXHIBIT 10.8 CONSULTING AGREEMENT This Consulting Agreement (herein referred to as ?Agreement?) is made and entered into as of January 1, 2022 (the ?Effective Date?), by and between Monopar Therapeutics Inc. (herein referred to as ?Monopar?), a Delaware corporation, located at 1000 Skokie Blvd, Suite 350, Wilmette, IL 60091, and Christopher M. Starr, Ph.D., (herein referred to as ?Consultant?), wh |
|
| March 24, 2022 |
Form of Restricted Stock Unit Grant Notice EXHIBIT 10.4 MONOPAR THERAPEUTICS INC. 2016 Stock Incentive Plan RESTRICTED STOCK UNIT GRANT NOTICE Monopar Therapeutics Inc. (the ?Company?) has awarded to Awardee the number of restricted stock units under its 2016 Stock Incentive Plan (the ?Plan?) set forth below (the ?Award?). Awardee: [[firstname]] [[lastname]] Date of Grant: [[grantdate]] Grant ID: [[grantnumber]] Number of Restricted Stock |
|
| March 24, 2022 |
2016 Stock Incentive Plan, as amended EXHIBIT 10.1 MONOPAR THERAPEUTICS INC. 2016 STOCK INCENTIVE PLAN (Share amounts have been adjusted to reflect a 70 for 1 stock split that took place on March 17, 2017) (As amended to date) 1. Purpose of the Plan. The purpose of this Plan is to enhance shareholder value by linking the compensation of officers, directors, key employees and consultants of the Company to increases in the price of Mono |
|
| February 15, 2022 |
Monopar Announces Clinical and Preclinical Program Updates EXHIBIT 99.1 Monopar Announces Clinical and Preclinical Program Updates - Validive Phase 2b/3 VOICE trial now open at 43 sites; active and enrolling in US and EU - Open-label Phase 1b camsirubicin trial: early signs of clinical benefit observed WILMETTE, Ill, February 15, 2022 ? Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary t |
|
| February 15, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February, 15 2022 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commis |
|
| December 8, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Deleware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commiss |
|
| December 8, 2021 |
Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial Exhibit 99.1 Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial WILMETTE, Ill, December 8, 2021 ? Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the positive recommendation fr |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2021 ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commis |
|
| November 12, 2021 |
EXHIBIT 99.1 Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments First Patients Dosed in Camsirubicin Phase 1b Clinical Trial in U.S. Validive? Phase 2b/3 VOICE Trial Cleared to Enroll in Europe and on Track for Reaching Interim in H1 2022 Wilmette, IL, November 12, 2021 ? Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-s |
|
| October 27, 2021 |
EXHIBIT 99.1 Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma WILMETTE, Ill, October 27, 2021 ? Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced |
|
| October 27, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commiss |
|
| September 16, 2021 |
EXHIBIT 99.1 Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma WILMETTE, Ill, September 16, 2021 ? Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced its |
|
| September 16, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commi |
|
| September 13, 2021 |
Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe EXHIBIT 99.1 Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe - Trial launch in Europe coincides with the Company?s upcoming presentation at the European Society for Medical Oncology Congress WILMETTE, Ill., September 13, 2021 ? Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or imp |
|
| September 13, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commi |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2021 ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THERA |
|
| August 12, 2021 |
Exhibit 99.1 Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates Camsirubicin Phase 1b Clinical Trial Anticipated to Start in the U.S. in Q4 2021 Validive? Phase 2b/3 VOICE Trial on Track for Reaching Interim Analysis in H1 2022 Wilmette, IL, August 12, 2021 ? Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceu |
|
| August 12, 2021 |
Employment Agreement of Jose Octavio Pinto Costa Filho - effective July 12, 2021 EXHIBIT 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is entered into as of May 13, 2021, by and between Jose Octavio Pinto Costa Filho, MD (?Executive?) and Monopar Therapeutics Inc. (the ?Company?). Whereas, the Company desires to employ Executive as its Chief Medical Officer, effective as of July 12, 2021 (the ?Effective Date?), and Executive desires |
|
| August 12, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissi |
|
| August 12, 2021 |
Employment Agreement of Andrew Cittadine - effective June 1, 2021 EXHIBIT 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is entered into as of May 11, 2021, by and between Andrew Cittadine (?Executive?) and Monopar Therapeutics Inc. (the ?Company?). Whereas, the Company desires to employ Executive as its Chief Operating Officer, effective as of June 1, 2021 (the ?Effective Date?), and Executive desires to serve in such |
|
| August 5, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissio |
|
| August 5, 2021 |
Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial Exhibit 99.1 Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive? VOICE Trial WILMETTE, Ill., August 5, 2021?? Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced it has successfully re |
|
| August 3, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissio |
|
| August 3, 2021 |
Exhibit 99.1 Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma WILMETTE, Ill., August 3, 2021?? Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced clear |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| July 12, 2021 |
Monopar Appoints Octávio Costa, MD, as Chief Medical Officer Exhibit 99.1 Monopar Appoints Oct?vio Costa, MD, as Chief Medical Officer WILMETTE, Ill., July 12, 2021?? Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Oct?vio Costa, MD, as Chief Medical Offic |
|
| July 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| June 24, 2021 |
Exhibit 99.1 Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive? Trial at MASCC/ISOO WILMETTE, Ill. June 24, 2021?? Monopar Therapeutics Inc. (Nasdaq: MNPR) a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients,?today announce |
|
| June 24, 2021 |
Exhibit 99.2 |
|
| June 24, 2021 |
Financial Statements and Exhibits, Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| June 3, 2021 |
EX-99 2 nuscollab.htm ADDITIONAL EXHIBITS Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer Development of novel Camsirubicin analog expands Monopar’s therapeutic pipeline WILMETTE, IL, June 3, 2021 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical compa |
|
| June 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| June 1, 2021 |
Monopar Therapeutics Expands Leadership Team with Appointment of Andrew Cittadine as Chief Operating Officer WILMETTE, Ill. |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| May 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| May 26, 2021 |
EX-99 2 mnpr-101compositionofmatt.htm ADDITIONAL EXHIBITS Monopar and NorthStar Announce Filing of Composition of Matter Patent Protecting MNPR-101 Radiotherapeutic WILMETTE, Ill. and BELOIT, Wis., May 26, 2021 – Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional composition of matter patent titled “Urokinase Plasminogen A |
|
| May 24, 2021 |
Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery Potential to significantly improve the yield of Actinium-based radiopharmaceuticals WILMETTE, Ill. |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2021 ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THER |
|
| May 13, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commission |
|
| May 13, 2021 |
EX-99 2 q12021earningsrelease0512.htm ADDITIONAL EXHIBITS Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates First Patient Dosed in Validive® Phase 2b/3 VOICE Clinical Trial Camsirubicin Run-in Clinical Trial Now Planned to Start in 2H 2021 Potential Utility Reported for MNPR-101 as Imaging Agent in Cancer Surgery Wilmette, IL, May 13, 2021 – Monopar Ther |
|
| May 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissio |
|
| March 30, 2021 |
Monopar?s uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study WILMETTE, Ill. |
|
| March 25, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2021 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39070 32-0463781 (State or other jurisdiction of incorporation) (Commissio |
|
| March 25, 2021 |
Subsidiaries of Monopar Therapeutics Inc. as of December 31, 2020 EX-21 3 exhibit21-1.htm SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 Subsidiaries of Monopar Therapeutics Inc. as of December 31, 2020 Name Direct Parent Ownership Jurisdiction of Incorporation Monopar Therapeutics Australia Ltd Pty Monopar Therapeutics Inc. 100% Australia Monopar Therapeutics, SARL Monopar Therapeutics Inc. 100% France |
|
| March 25, 2021 |
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates Validive? Phase 2b/3 VOICE Clinical Trial Commenced Camsirubicin Phase 2 Clinical Trial Anticipated to Start in Q2 2021 MNPR-101-Conjugate Data Published in European Journal of Cancer Wilmette, IL, March 25, 2021 ? Monopar Therapeutics Inc. |
|
| March 25, 2021 |
Annual Report - PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2020 ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THERAPEUT |
|
| March 25, 2021 |
Consulting Agreement of pRx Consulting (Patrice Rioux) – effective January 1, 2020 EX-10 8 prxconsulting2020agreemen.htm MATERIAL CONTRACTS Exhibit 10.11 CONSULTING AGREEMENT This Consulting Agreement (herein referred to as “Agreement”) is made and entered into on January 30, 2020, effective as of January 1, 2020 (the “Effective Date”), by and between Monopar Therapeutics, Inc. (herein referred to as “Monopar”), a Delaware corporation, located at 1000 Skokie Blvd., Suite 350, Wi |
